Evidence map›Paper›PMID 41165026›Full record

ReviewAsia-Pacific journal of clinical oncology2026

Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.

Al-Yafie Shikaha Ahmed Y, Lee Wei Shyn, Pong Ben Jun Xiang, Rajendran Dhanusha, Tesfagin Reem Michael, Wei Hsum Yap, Bey Hing Goh, Rebecca Shin-Yee Wong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Al-Yafie Shikaha Ahmed YSunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University. No 5, Jalan Universiti, Petaling Jaya, Malaysia.
Lee Wei ShynSunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University. No 5, Jalan Universiti, Petaling Jaya, Malaysia.
Pong Ben Jun XiangSunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University. No 5, Jalan Universiti, Petaling Jaya, Malaysia.
Rajendran DhanushaSunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University. No 5, Jalan Universiti, Petaling Jaya, Malaysia.
Tesfagin Reem MichaelSunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University. No 5, Jalan Universiti, Petaling Jaya, Malaysia.
Wei Hsum YapSchool of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, No. 1sJalan Taylor's, Subang Jaya, Malaysia.
Bey Hing GohSunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University. No 5, Jalan Universiti, Petaling Jaya, Malaysia.ORCID https://orcid.org/0000-0003-1006-3649
Rebecca Shin-Yee WongDepartment of Medical Education, Faculty of Medical and Life Sciences, Sunway University, No. 5, Jalan Universiti, Petaling Jaya, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematologic malignancies are cancers that affect the bone marrow, lymphatic system, and hematopoietic cells, resulting in various cancer subtypes and clinical manifestations. Currently, tissue biopsy in hematological malignancies is typically performed for genomic profiling and has limitations such as invasiveness, lengthy procedures, and high expense. On the other hand, liquid biopsy serves as an emerging tool used for examining the blood or other bodily fluids of patients, for the purpose of identifying genetic mutations, biomarkers, or cancer-related substances. Liquid biopsy biomarkers include circulating tumor DNA (ctDNA), microRNA (miRNA), and exosomes. In the context of hematological malignancies, these biomarkers offer valuable insights into disease etiology, enabling effective disease monitoring and guiding treatment decisions owing to their differential expression patterns. This review critically examines the recent advancements and effectiveness of liquid biopsy biomarkers in the areas of diagnosis, therapy, and monitoring. The challenges and future directions of liquid biopsy for hematological malignancies are also discussed.

Indexed as

Biomarkers, TumorHematologic NeoplasmsCirculating Tumor DNAHumansLiquid BiopsyMicroRNAsBiomarkers, TumorCirculating Tumor DNAMicroRNAscirculating tumor DNA (ctDNA)exosomeshematologic malignanciesliquid biopsymicroRNAs (miRNAs)

Identifiers

PMID41165026
PMCPMC13568961

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.